{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:33:07Z","timestamp":1788845587816,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AR062522"],"award-info":[{"award-number":["R01AR062522"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.bone.2014.10.012","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T01:51:19Z","timestamp":1414029079000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment"],"prefix":"10.1016","volume":"71","author":[{"given":"Benjamin P.","family":"Sinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Caird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Kozloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bone.2014.10.012_bb0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"26","key":"10.1016\/j.bone.2014.10.012_bb0010","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","article-title":"Osteogenesis imperfecta after the menopause","volume":"310","author":"Paterson","year":"1984","journal-title":"N Engl J Med"},{"issue":"9419","key":"10.1016\/j.bone.2014.10.012_bb0015","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2014.10.012_bb0020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.bone.2014.10.012_bb0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.bone.2014.10.012_bb0030","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.bone.2014.10.012_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.bone.2014.10.012_bb0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrendo.2009.58","article-title":"Bone: use of bisphosphonates in children-proceed with caution","volume":"5","author":"Marini","year":"2009","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.bone.2014.10.012_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","article-title":"Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen","volume":"18","author":"Marini","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.bone.2014.10.012_bb0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","article-title":"Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis","volume":"129","author":"Antoniazzi","year":"1996","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.bone.2014.10.012_bb0055","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"issue":"13","key":"10.1016\/j.bone.2014.10.012_bb0060","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"20","key":"10.1016\/j.bone.2014.10.012_bb0065","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.bone.2014.10.012_bb0070","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bone.2014.10.012_bb0075","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bone.2014.10.012_bb0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3109\/17453674.2011.625539","article-title":"Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats","volume":"82","author":"Agholme","year":"2011","journal-title":"Acta Orthop"},{"issue":"9","key":"10.1016\/j.bone.2014.10.012_bb0085","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bone.2014.10.012_bb0095","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"53","key":"10.1016\/j.bone.2014.10.012_bb0100","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","article-title":"Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an \u03b11(I) G349C substitution","volume":"274","author":"Forlino","year":"1999","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.bone.2014.10.012_bb0105","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1359\/JBMR.040111","article-title":"Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength","volume":"19","author":"Kozloff","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.bone.2014.10.012_bb0110","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.bone.2014.10.012_bb0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bone.2011.12.007","article-title":"Increased susceptibility to microdamage in Brtl\/+ mouse model for osteogenesis imperfecta","volume":"50","author":"Davis","year":"2012","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2013.06.003","article-title":"Fracture healing with alendronate treatment in the Brtl\/+ mouse model of osteogenesis imperfecta","volume":"56","author":"Meganck","year":"2013","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2014.10.012_bb0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.bone.2014.10.012_bb0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2008-12-195859","article-title":"In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta","volume":"114","author":"Panaroni","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.10.012_bb0140","first-page":"1","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"7","author":"Sinder","year":"2014","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.bone.2014.10.012_bb0145","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bone.2009.07.078","article-title":"Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD","volume":"45","author":"Meganck","year":"2009","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1979","journal-title":"IEEE Trans Syst Man Cybern"},{"issue":"6","key":"10.1016\/j.bone.2014.10.012_bb0155","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.bone.2014.10.012_bb0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jbmr.548","article-title":"Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation","volume":"27","author":"Bivi","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bone.2014.10.012_bb0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S8756-3282(99)00194-5","article-title":"Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach","volume":"25","author":"Hauge","year":"1999","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2014.10.012_bb0175","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/art.30385","article-title":"Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone","volume":"63","author":"Marenzana","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.bone.2014.10.012_bb0180","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.bone.2014.10.012_bb0185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jmg.25.3.200","article-title":"Sclerosteosis","volume":"25","author":"Beighton","year":"1988","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/8756-3282(86)90152-3","article-title":"Quantitative measurements of periosteal and cortical\u2013endosteal bone formation and resorption in the midshaft of female rat femur","volume":"7","author":"Sontag","year":"1986","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2014.10.012_bb0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/wsbm.15","article-title":"Systems analysis of bone","volume":"1","author":"Jepsen","year":"2009","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"27","key":"10.1016\/j.bone.2014.10.012_bb0200","first-page":"1105","article-title":"Endocrine function in sclerosteosis","volume":"55","author":"Epstein","year":"1979","journal-title":"S Afr Med J"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214003858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214003858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T10:47:09Z","timestamp":1565952429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328214003858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":40,"alternative-id":["S8756328214003858"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2014.10.012","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2014.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}